However, controversy exists over the capacity of Keap1 to function as a tumor suppressor in the context of KrasG12D-driven lung cancer18–21, where the ability to accelerate tumorigenesis in the absence of additional loss-of-function mutations in p53 or Lkb1 remains unclear18. The gene discussed is TP53; the disease is neoplasm.